Colombian Cannabis: Showcases a study of the effects of cannabidiol (CBD) on schizophrenia
COLOMBIAN CANNABIS presents a study published in the American Journal of Psychiatry focusing on how cannabidiol (CBD) affects humans and animals suffering from schizophrenia. The study’s results’ suggests that CBD has a positive effect on humans and animals suffering from schizophrenia.
Research in both animals and humans indicates that cannabidiol (CBD) has antipsychotic properties. The authors assessed the safety and effectiveness of CBD in patients with schizophrenia.
These findings suggest that CBD has beneficial effects in patients with schizophrenia. As CBD’s effects do not appear to depend on dopamine receptor antagonism, this agent may represent a new class of treatment for the disorder.”
The full article can be found at: https://ajp.psychiatryonline.org/doi/abs/10.1176/appi.ajp.2017.17030325
A video of the article can be found at: https://www.youtube.com/watch?v=aT8aaRf9xS0&list=PL9BMKzYDhMNLYAVKgsQpecFBxZaGq98i0
To find more studies about schrizophrenia: http://www.colombiancannabis.co/cannabis-detalle.php?L=S&id=Ng==&p=NA==